

# Almirall receives the qualification "Excellent" in the Profarma 2020 program

- **Almirall has obtained consecutively the highest qualification granted by this program since it was created in 1986**

**BARCELONA, Spain. May 5 2021 – Almirall S.A. (BME: ALM)**, a global biopharmaceutical company, has obtained the highest rating by the Profarma program, an initiative of the Spanish Government aimed to foster competitiveness in the Spanish pharmaceutical industry by evaluating the level of excellence in terms of innovation, R&D, manufacturing and economic results. The rating of “Excellent” recognizes and reinforces Almirall’s dedication and commitment to research and development, as well as its focus on science and innovation.

Almirall invested around 10% of its annual Net Sales in 2020 in R&D, with 14% of its workforce -248 scientists- running two cutting-edge R&D centres located in Spain and Germany.

The Profarma assessment -a joint initiative by the Ministry of Industry, Trade and Tourism and the Ministry of Health, Consumer Affairs and Social Welfare- has become a valuable tool for the recognition and transparency of the pharmaceutical companies that are present in the country. The primary aim of the program, to increase the competitiveness of the pharmaceutical industry in Spain, is achieved through the promotion of those activities that prove to be essential and provide greater added value, such as investment in new industrial plants and new technologies for production, and fostering research, development and innovation.

Almirall has been participating in the Profarma program since it was created in 1986. During all these 34 years, it has received an Excellent rating in each and every one of its editions.

*“This recognition acknowledges the continued effort from Almirall’s R&D team to provide novel solutions to patients with dermatological conditions. In particular, we highlight the recent incorporation of capacities to identify and progress biological treatments such as monoclonal antibodies or gene therapies”,* states Jorge Beleta, Almirall’s R&D Institutional Relations Director.

## About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

**For more information, please visit [almirall.com](https://almirall.com)**

**Almirall Corporate Communications contact:**

Ester Riu

[ester.riu@almirall](mailto:ester.riu@almirall)

Phone: (+34) 671 580 438

**Almirall Investors’ relations contact:**

Pablo Divasson del Fraile

[pablo.divasson@almirall.com](mailto:pablo.divasson@almirall.com)

Tel.: (+34) 932 913 087